Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Lancet Diabetes Endocrinol.

Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA

doi: 10.1016/S2213-8587

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Statins for children with familial hypercholesterolemia

Cochrane Database Syst Rev.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U

doi: 10.1002/14651858.

RECOMMENDED

Lipid-Lowering Drugs

Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program

Atherosclerosis.

Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR

doi: 10.1016/j.atherosclerosis.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials

J Pharm Pharm Sci.

Eslami SM, Nikfar S, Ghasemi M, Abdollahi M

doi: 10.18433/J36C8N.

RECOMMENDED

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Coll Cardiol.

Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ

doi: 10.1016/j.jacc.2019.12.020.

Lipid-Lowering Drugs

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

JAMA Cardiol.

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ

doi: 10.1001/jamacardio.

Therapy and Intervention

Late Restenosis After Both First-Generation and Second-Generation Drug-Eluting Stent Implantations Occurs in Patients With Drug-Eluting Stent Restenosis

Circ Cardiovasc Interv.

Habara S, Kadota K, Kuwayama A, Shimada T, Ohya M, Miura K, Amano H, Kubo S, Hyodo Y, Otsuru S, Tada T, Tanaka H, Fuku Y, Goto T

doi: 10.1161/

Cardiovascular Risk and Diseases

Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes

J Am Coll Cardiol.

D'Erasmo L, Minicocci I, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L, Mata P, Sánchez-Hernández RM, Prieto-Matos P, Real JT, Ascaso JF, Lafuente EE, Pocovi M, Fuentes FJ, Muntoni S, Bertolini S, Sirtori C, Calabresi L, Pavanello C, Averna M, Cefalu AB, Noto D, Pacifico AA, Pes GM, Harada-Shiba M, Manzato E, Zambon S, Zambon A, Vogt A, Scardapane M, Sjouke B, Fellin R, Arca M

doi: 10.1016/j.jacc.2017.11.028.

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations

J Am Coll Cardiol.

Stein EA, Dann EJ, Wiegman A, Skovby F, Gaudet D, Sokal E, Charng MJ, Mohamed M, Luirink I, Raichlen JS, Sundén M, Carlsson SC, Raal FJ, Kastelein JJP

doi: 10.1016/j.jacc.2017.06.058.

Related content

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Statins for children with familial hypercholesterolemia

Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

Late Restenosis After Both First-Generation and Second-Generation Drug-Eluting Stent Implantations Occurs in Patients With Drug-Eluting Stent Restenosis

Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations